BACKGROUND: It is unclear how stable low-level viral replication and CD4 cell numbers can be maintained under highly active antiretroviral therapy (HAART). This study was designed to analyse whether HIV-specific responses in stable partially controlled patients during antiretroviral therapy (ART) differ from those observed in complete HAART failure and whether they contribute to the control of viral load (VL). METHODS: Three groups of patients were selected according to plasma HIV RNA levels during 18 months of ART: persistently low VL (LoVL; HIV RNA <10,000 copies/ml; n = 28), undetectable VL (UnVL; HIV RNA <200 copies/ml; n = 29) and high VL (HiVL; HIV RNA >10,000 copies/ml; n = 14). T-cell responses were studied using lymphoproliferative and interferon (IFN)-gamma-ELISpot assays against HIV-p24, -gp160, recall antigens, and 15 pools of HIV-(Gag + RT) peptides. RESULTS: Frequencies of IFN-gamma-producing CD4 T cells against HIV-p24 were higher in LoVL than in UnVL or HiVL groups [median, 131, 47 and 23 spot-forming cells (SFC)/1 x 10 peripheral blood mononuclear cells (PBMC), respectively; P = 0.012 and P = 0.047]. Lymphoproliferative responses to HIV-p24 and recall antigens were similar in LoVL and UnVL groups but lower in HiVL (P = 0.004). Frequencies of HIV-specific CD8 T cells were higher in LoVL than in UnVL (1340 versus 410 SFC/1 x 10 PBMC; P = 0.001). They correlated negatively with VL in the LoVL and HiVL (r, -0.393, P = 0.039 and r, -0.643, P = 0.024, respectively) and positively correlated with anti-HIV CD4 cell frequencies in the LoVL group only (r, 0.420; P = 0.026). CONCLUSION: Persistently low viral replication (<10,000 copies/ml) during ART stimulates high frequencies of HIV-specific CD4 and CD8 T cells compared to full virus suppression or complete ART failure. The association of high anti-HIV activity with large numbers of HIV-specific CD8 T cells contribute to the control of viral replication.
BACKGROUND: It is unclear how stable low-level viral replication and CD4 cell numbers can be maintained under highly active antiretroviral therapy (HAART). This study was designed to analyse whether HIV-specific responses in stable partially controlled patients during antiretroviral therapy (ART) differ from those observed in complete HAART failure and whether they contribute to the control of viral load (VL). METHODS: Three groups of patients were selected according to plasma HIV RNA levels during 18 months of ART: persistently low VL (LoVL; HIV RNA <10,000 copies/ml; n = 28), undetectable VL (UnVL; HIV RNA <200 copies/ml; n = 29) and high VL (HiVL; HIV RNA >10,000 copies/ml; n = 14). T-cell responses were studied using lymphoproliferative and interferon (IFN)-gamma-ELISpot assays against HIV-p24, -gp160, recall antigens, and 15 pools of HIV-(Gag + RT) peptides. RESULTS: Frequencies of IFN-gamma-producing CD4 T cells against HIV-p24 were higher in LoVL than in UnVL or HiVL groups [median, 131, 47 and 23 spot-forming cells (SFC)/1 x 10 peripheral blood mononuclear cells (PBMC), respectively; P = 0.012 and P = 0.047]. Lymphoproliferative responses to HIV-p24 and recall antigens were similar in LoVL and UnVL groups but lower in HiVL (P = 0.004). Frequencies of HIV-specific CD8 T cells were higher in LoVL than in UnVL (1340 versus 410 SFC/1 x 10 PBMC; P = 0.001). They correlated negatively with VL in the LoVL and HiVL (r, -0.393, P = 0.039 and r, -0.643, P = 0.024, respectively) and positively correlated with anti-HIV CD4 cell frequencies in the LoVL group only (r, 0.420; P = 0.026). CONCLUSION: Persistently low viral replication (<10,000 copies/ml) during ART stimulates high frequencies of HIV-specific CD4 and CD8 T cells compared to full virus suppression or complete ART failure. The association of high anti-HIV activity with large numbers of HIV-specific CD8 T cells contribute to the control of viral replication.
Authors: A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon Journal: J Virol Date: 2007-08-01 Impact factor: 5.103
Authors: Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht Journal: J Virol Date: 2006-06 Impact factor: 5.103
Authors: A Samri; C Durier; A Urrutia; I Sanchez; H Gahery-Segard; S Imbart; M Sinet; E Tartour; J-P Aboulker; B Autran; A Venet Journal: Clin Vaccine Immunol Date: 2006-06
Authors: M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French Journal: J Immunol Date: 2015-04-24 Impact factor: 5.422
Authors: Koen K A Van Rompay; Lucie Durand-Gasselin; Laurie L Brignolo; Adrian S Ray; Kristina Abel; Tomas Cihlar; Abigail Spinner; Christopher Jerome; Joseph Moore; Brian P Kearney; Marta L Marthas; Hans Reiser; Norbert Bischofberger Journal: Antimicrob Agents Chemother Date: 2008-06-23 Impact factor: 5.191
Authors: Pedro Castro; Montserrat Plana; Raquel González; Anna López; Anna Vilella; Jose M Nicolas; Teresa Gallart; Tomàs Pumarola; José M Bayas; José M Gatell; Felipe García Journal: AIDS Res Hum Retroviruses Date: 2012-12-16 Impact factor: 2.205
Authors: Koen K A Van Rompay; Kristin A Trott; Kartika Jayashankar; Yongzhi Geng; Celia C LaBranche; Jeffrey A Johnson; Gary Landucci; Jonathan Lipscomb; Ross P Tarara; Don R Canfield; Walid Heneine; Donald N Forthal; David Montefiori; Kristina Abel Journal: Retrovirology Date: 2012-07-17 Impact factor: 4.602